Desmoid Tumor
Conditions
Interventions
Case series:pharmacotherapy 50mg/2 times/d
Sponsors
Peking University Cancer Hospital
Eligibility
Sex/Gender
All
Age
10 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1. Pathologically confirmed desmoid tumor and unsuccessful imatinib desmoid tumor therapy history. 2. Existing measurable focus according to RECIST1.1 3. Male and Female,age=10 years old,<70 years old. 4. ECOG performance score 0-2. 5. Conform to the following criteria for inoperable cases after radiographic evaluation: (1) the radical resection will cause massive defect of soft tissue and result in loss of limb function and huge change of appearance; (2) the radical resection will implicate the main nerves and vessels; (3) the tumor is invasive to the bone; (4) the patients refuse surgery; (5) amputation is not considered. 6. Informed patient or the legal guardian of underaged patient, and signed informed consent; 7. Good patients compliance, voluntary acceptance of follow-up, treatment, laboratory examination and other research steps.
Exclusion criteria
Exclusion criteria: 1. AST and/or ALT>2.5×ULN, or TSB>1.5×ULNCr>1.5×ULN; 2. The absolute value of ANC<1.5×10^9/L, or blood platelet <75×10^9/L, or Hb<90g/L; 3. Diagnosed with malignant tumor within 5 years, except adequately treated skin basal cell carcinoma or carcinoma in situ of cervix; 4. Diagonsed with any of the following diseases within 12 months of enrollment: myocardial infarction severe/unstable anginacoronary arterial/peripheral arterial bypass grafting, symptomatic congestive heart failure or cerebrovascular accident; 5. Serum HIV antibody positive; 6. Currently enrolled in other clinical trial; 7. Pregnant or fertile women without contraceptive measures; 8. Diagnosed with other severe acute or chronic dysfunction or mental health problems, abnormal laboratory examination results, would increase the risk of joining research or using medication, interfering the result of research, unfit for enrollment after researchers judgment.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| progression free survival (PFS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Complete Remission (CR);Partial Remission (PR);progression of disease (PD);stable disease (SD);tumor control probability (CR+PR+SD); | — |
Countries
China
Contacts
Public ContactLi shu
Peking University Cancer Hospital
Outcome results
None listed